FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Biologics

Workforce, Education for Regenerative Medicine

The Government Accountability Office reports on regenerative medicine and advanced therapies workforce and education/training needs.

latest-news-card-1
FDA General

OSTP Goals for Biotechnology and Biomanufacturing

A new White House Office of Science and Technology Policy (OSTP) report lists 10 bold goals for the U.S. biotechnology and biomanufacturing.

latest-news-card-1
Medical Devices

Device Cybersecurity is Top Concern for Shuren

CDRH director Jeff Shuren tells an Alliance for Stronger FDA Webinar that cybersecurity is one of the biggest concerns that keeps him up at night.

latest-news-card-1
Human Drugs

Cidar/Melintas Rezzayo Wins FDA Approval

FDA approves a Cidara Therapeutics and Melinta Therapeutics NDA for Rezzayo (rezafungin for injection) for treating candidemia and invasive candidiasi...

latest-news-card-1
Human Drugs

Consider Antitrust in Apokyn Generic Case: FTC

The Federal Trade Commission asks the Delaware federal court to consider four antitrust implications in deciding whether to grant a Supurnus motion to...

latest-news-card-1
Human Drugs

Complete Response for AbbVie Parkinsons NDA

FDA issues AbbVie a complete response letter for ABBV-951 (foscarbidopa/foslevodopa) for treating motor fluctuations in adults with advanced Parkinson...

latest-news-card-1
Medical Devices

Registry Set Up for Breast Implant Carcinoma Reports

FDA says events involving squamous cell carcinoma in the scar tissue (capsule) that forms around breast implants should be reported to a registry deve...

latest-news-card-1
Federal Register

Shionogis Mulpleta Regulatory Review Period

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Shionogi & Co.s Mulpleta (lusutrombopag).

latest-news-card-1
Federal Register

Regulatory Review Period for Galafold

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Amicus Therapeutics Galafold (migalastat).

latest-news-card-1
Human Drugs

Contradictory Info in P&G Nyquil Filing: FDA

FDA warns Procter & Gamble (P&G) about unresolved contradictory information in the electronic listing for one of its Nyquil products and the product l...